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Background
At least 100 mutations in the TTR gene are known to
cause ATTR amyloidosis. Limited information is available
with regard to the progression of cardiac involvement in
different amyloidogenic TTR mutations. This study inves-
tigates clinical characteristics and cardiac involvement of
some ATTR-associated genotypes in the Netherlands.
Methods
Clinical data and information with regard to survival was
collected for all ATTR patients between 1994 and 2014
in the University Medical Centre Groningen, which is the
Dutch national centre of expertise. In total 114 consecu-
tive patients carrying 10 different TTR mutations were
admitted. Patients were divided into different groups
based on their mutation. Only mutations present in more
than 5 patients were included for further analysis. The
TTR mutations studied were Val71Ala (n=9), Tyr114Cys
(n=21) and Val30Met (n=31). For each mutation clinical
and demographical characteristics, laboratory measure-
ments and echocardiography data were collected at base-
line and follow-up. Baseline was determined as time of
diagnosis based on histological confirmation of amyloid,
end of follow-up was defined as the last complete mea-
surement available. The primary endpoint was the devel-
opment of heart failure (HF) at follow-up, defined as
NT-proBNP plasma levels above 125 ng/L.
Results
Patients were predominantly male (59%). Mean follow-up
was 6 + 4 years and did not differ among the mutations
(P=0.144). Patients with the Val71Ala and Tyr114Cys
genotypes were younger at diagnosis compared to the
Val30Met genotype (44 and 50 vs.55 years respectively;
P=0.057). Most patients presented with neurological
symptoms (79%) and most of the remaining patients pre-
sented because of familial amyloidosis (10 %). At baseline
the NT-proBNP levels were raised in Val71Ala (11%), in
Tyr114Cys (14%) and inVal30Met (35%). NT-proBNP
levels did not differ among the mutations; median
20 (18-28), 97 (64-288) and 170 (112-365) ng/L (P=
0.096). At follow-up, NT-proBNP levels of only Val71Ala
and Val30Met increased further, median increase 206
(44-221) and 194 (89-706) ng/L (P=0.043 & P<0.001).
Echocardiography in patients with Val30Met showed an
increase in thickness of septal wall and posterior wall,
median 2 (0-4) and 3 (0-3) mm as compared to the other
mutations (p=0.005 & p<0.001). The 5-year survival rates
among mutations were similar (78%, 81% vs. 81%,
P=0.978).
Conclusions
During follow-up, levels of NT-proBNP in both
Val71Ala and Val30Met patients increased significantly,
whereas the posterior wall thickness in Val30Met also
increased. These results signify that despite initial pre-
sentation with neurological symptoms, cardiac involve-
ment is already present and progressive in some of the
TTR mutations.
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